Erick Maronak, manager of the Victory Large Cap Growth Fund, says Apple is the best-run company in the U.S., helping to make it the most attractive stock investment.
The $80 million mutual fund, which garners three of five stars from Morningstar, has returned more than 36% over the past year. The fund has risen an average of 2% annually during the past five years, better than 72% of its Morningstar-tracked peers.
Teva is just as dominant in generic pharmaceuticals and, given the dollar value of branded pharmaceuticals that are expected to lose patent protection, the company's growth prospects look as healthy as ever. The vertically integrated generic manufacturer will benefit irrespective of any health-care reform as it provides the lowest-cost alternatives to branded companies. The $50 billion company is expected to grow earnings 17% yet sells for 14 times 2010 estimated earnings.